Department of Pathology, and Department of Medical Oncology of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Department of Pathology, Key Laboratory of Disease Proteomics of Zhejiang Province, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Hum Mutat. 2020 Sep;41(9):1588-1599. doi: 10.1002/humu.24059. Epub 2020 Jul 5.
Co-occurring and mutually exclusive gene alteration events are helpful for understanding carcinogenesis but systematic screening for such events is quite limited. We conducted pairwise screening tests to identify "hit pairs" in colorectal cancer (CRC) by utilizing the cross-omics data from The Cancer Genome Atlas (TCGA). Numerous hit pairs involving somatic mutations, copy number variations, and DNA methylation were found to occur nonrandomly in CRC, such as KRAS and HOXB6, SMAD4 and PMEPA1. Based on these hit pairs, we identified 32 synthetic lethal pairs and 7,527 co-occurring pairs relating to drug response. Our further biological experiments showed that the co-occurrence of mutant FCGBP and NUDT12 silencing (or mutant TMC3 and RPS6KA6 silencing) with small interfering RNA reduced cell viability. Moreover, novel hit pairs could influence prognosis. The patients who carried concurrent mutations of IRF5 and NEFH, SYNE1 and TTN, or MUC16 and NEFH had worse survival outcomes. Particularly, the presence of mutant SYNE1 and TTN pair not only affects prognosis, but also is related to CRC patients' response to drug treatment. Our "hit pair" genes may provide insights into colorectal carcinogenesis and help open new avenues for CRC therapy.
同时发生和互斥的基因改变事件有助于理解致癌作用,但系统地筛选此类事件的范围相当有限。我们通过利用癌症基因组图谱(TCGA)的跨组学数据,进行了成对筛选测试,以鉴定结直肠癌(CRC)中的“命中对”。大量涉及体细胞突变、拷贝数变异和 DNA 甲基化的命中对在 CRC 中被发现是非随机发生的,例如 KRAS 和 HOXB6、SMAD4 和 PMEPA1。基于这些命中对,我们确定了 32 对合成致死对和 7527 对与药物反应相关的同时发生对。我们进一步的生物学实验表明,突变 FCGBP 和 NUDT12 沉默(或突变 TMC3 和 RPS6KA6 沉默)与小干扰 RNA 共同作用会降低细胞活力。此外,新的命中对可能会影响预后。同时携带 IRF5 和 NEFH、SYNE1 和 TTN 或 MUC16 和 NEFH 突变的患者生存结局较差。特别是,突变 SYNE1 和 TTN 对的存在不仅影响预后,而且与 CRC 患者对药物治疗的反应有关。我们的“命中对”基因可能为结直肠癌的致癌作用提供新的见解,并为 CRC 的治疗开辟新的途径。